HC Wainwright Reiterates Buy Rating for Aemetis (NASDAQ:AMTX)

HC Wainwright reaffirmed their buy rating on shares of Aemetis (NASDAQ:AMTX) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $28.00 target price on the specialty chemicals company’s stock.

AMTX has been the subject of several other research reports. Ascendiant Capital Markets dropped their price objective on shares of Aemetis from $20.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Truist Financial reissued a “hold” rating and set a $3.50 price target (down from $4.00) on shares of Aemetis in a research note on Wednesday, July 31st. StockNews.com raised Aemetis to a “sell” rating in a research note on Wednesday, July 31st. Finally, UBS Group decreased their price objective on Aemetis from $8.25 to $7.75 and set a “buy” rating on the stock in a report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.95.

Aemetis Trading Down 5.9 %

Shares of AMTX opened at $3.83 on Friday. Aemetis has a 12-month low of $2.10 and a 12-month high of $7.03. The company has a market capitalization of $190.50 million, a PE ratio of -1.69 and a beta of 1.23. The business’s 50 day moving average is $2.80 and its 200 day moving average is $3.05.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.09. The company had revenue of $81.44 million for the quarter, compared to the consensus estimate of $77.79 million. During the same quarter in the previous year, the business earned ($0.59) EPS. Equities research analysts predict that Aemetis will post -2.1 earnings per share for the current year.

Institutional Investors Weigh In On Aemetis

Several institutional investors have recently modified their holdings of AMTX. FMR LLC raised its holdings in Aemetis by 68.2% during the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after buying an additional 9,137 shares during the period. SG Americas Securities LLC bought a new position in Aemetis during the first quarter valued at $60,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Aemetis in the first quarter valued at $84,000. Hutchinson Capital Management CA purchased a new stake in shares of Aemetis in the second quarter valued at $70,000. Finally, Barclays PLC lifted its holdings in shares of Aemetis by 274.6% in the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock worth $109,000 after acquiring an additional 34,816 shares during the last quarter. 27.02% of the stock is owned by institutional investors.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.